Show me Q2 2025 earnings call Q&A session for abbvie

### Detailed Q&A Breakdown

1) Analyst: Mohit Bansal, Wells Fargo
– The question: Regarding the impact of Stelara’s biosimilar on SKYRIZI and RINVOQ, especially SKYRIZI’s dynamics. How does it compare with the Humira biosimilar situation?
– The response: Jeff from AbbVie explains that, like with Humira, there is some shift but SKYRIZI’s growth is largely due to its superior data and connection with physicians. Rob adds that their product, SKYRIZI, showed significant gains in head-to-head trials against STELARA, contributing to its strong momentum, independent of biosimilar effects.

2) Analyst: Terence Flynn, Morgan Stanley
– The question: Can you discuss SKYRIZI’s and RINVOQ’s strong performance and any potential impact from EU tariffs moving forward?
– The response: Raul states that they’re performing strongly, well in line with, if not exceeding, long-term guidance. Tariffs are yet uncertain as the details need to be clear, though AbbVie is structurally well-positioned to handle such changes due to their U.S. manufacturing capabilities.

3) Analyst: Chris Schott, JPMorgan
– The question: What is driving SKYRIZI’s meaningful upside this year, and does it vary by indication? How does AbbVie view pipeline growth beyond 2030?
– The response: Jeff explains that growth is balanced across indications, especially in psoriatic diseases. Rob highlights AbbVie’s focus on building a pipeline that sustains growth beyond the current major drivers like SKYRIZI and RINVOQ.

4) Analyst: Dave Reisinger, Leerink Partners
– The question: How do you plan to use your global aesthetics footprint for obesity drugs in the future, and what about expanding your R&D portfolio in obesity?
– The response: Jeff states that AbbVie is strategically well-positioned to leverage their aesthetics market exposure for obesity-related treatments. Rupol mentions they’re exploring innovations in the amylin class, focusing on new partners for combination therapies.

5) Analyst: Carter Gould, Cantor
– The question: Is BIOLEV’s raised guidance driven more by the U.S. or OUS markets, and has this influenced the U.S. launch expectations?
– The response: Jeff confirms international demand, especially the stability and impressiveness of OUS performance, guiding the revenue upgrade more so than specific U.S. factors.

6) Analyst: Tim Anderson, Bank of America
– The question: How do you view upcoming IRA negotiations for Vraylar and its potential impact? Also, what is your perspective on the impact of GLP-1s on Botox and dermal fillers?
– The response: Rob states that they’ll provide details post-negotiations but highlights a recent exemption change for VENCLEXTA in IRA. Jeff assures GLP-1s are a net neutral factor in aesthetics, with certain headwinds due to macro issues rather than direct competition.

7) Analyst: Vamil Divan, Guggenheim Securities
– The question: How significant is the alopecia areata opportunity for RINVOQ, and what macroeconomic trends are impacting aesthetics?
– The response: Jeff indicates alopecia areata regimes could significantly bolster RINVOQ’s sales. He points out that the current consumer sentiment in aesthetics is driven by economic factors more than any structural change in market dynamics.

8) Analyst: Steve Scala, TD Cowen
– The question: Why does the current economic uncertainty affect aesthetics more compared to past disruptions? What about advances in your potential anti-amyloid antibody?
– The response: Jeff acknowledges chronic macro pressures unlike previous episodes, with customer sentiments shifting slightly against invasive procedures. Rupol describes the promising aspects of their anti-amyloid project, anticipating further advancements in Alzheimer’s treatment.

9) Analyst: Chung Nguyen, UBS
– The question: Can you discuss the pricing trends for SKYRIZI, especially with IBD scripts considered, and does it align with overall expectations?
– The response: Scott clarifies price fluctuations due to specific pricing dynamics in the first half but expects near-neutral annual pricing with these considered, showing slight growth favorability.

10) Analyst: Gary Nachman, Raymond James
– The question: What competitive dynamics do you see in IL-twenty three against SKYRIZI, and how is neuro strong despite potential pricing challenges?
– The response: Jeff cites robust expansion capability in IBD for IL-twenty three, with ample leverage in other areas as well. Scott affirms neuro’s strength is volume-driven, supported by slight pricing benefits.

11) Analyst: Assad Haynor, Goldman Sachs
– The question: Regarding the PD-One VEGF class, how does AbbVie’s outlook fit amid recent BD activities, and what might drive future engagements?
– The response: Rupol expresses intent to explore partnerships that enhance ADC platforms within oncology, aimed at leveraging this class along with ongoing developments.

### Sentiment Score Distribution Table

### Sentiment Score Conclusion

The overall sentiment from the earnings call was largely positive, with several analysts highlighting strong growth trajectories and financial robustness across AbVie’s portfolio. Scores spanning from 8 to 9 reflect strong confidence in pipeline management and strategic expansion plans. Concerns noted include the macroeconomic impacts on the aesthetics market and regulatory uncertainties surrounding IRA negotiations, reflected in the slightly lower ratings from Tim Anderson and Steve Scala. However, sentiment around core growth products like SKYRIZI and RINVOQ, as well as strategic R&D directions in obesity and neuroscience, underscore strong market approval, pointing to AbVie’s strategic market adaptability and growth potential. Concerns remain around how ongoing pressure in aesthetics might affect future performance, though these are largely mitigated by reassuring forward-looking statements on innovation and market adaptations.